Supplementary Figure 17 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
<p>Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.</p>
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Eará dahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Almmustuhtton: |
2025
|
| Fáttát: | |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|